Protagonist Therapeutics, Inc
PTGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001377121
In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q2 2025
Institutional positions in Protagonist Therapeutics, Inc as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 274
- +3 vs. Q1 2025
- Shares held
- 71.0M
- +5.66M (+8.7%) vs. Q1 2025
- Total value
- $3.92B
- +$774.8M (+24.6%) vs. Q1 2025
- New holders
- 52
- 120 more added
- Sold out
- 49
- 76 more reduced
4 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTGX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 346 | $9.30B |
| Q1 2026 | 322 | $8.31B |
| Q4 2025 | 319 | $6.18B |
| Q3 2025 | 275 | $4.70B |
| Q2 2025 | 274 | $3.92B |
| Q1 2025 | 275 | $3.15B |
| Q4 2024 | 241 | $2.44B |
| Q3 2024 | 240 | $2.78B |
| Q2 2024 | 188 | $2.05B |
| Q1 2024 | 185 | $1.73B |
| Q4 2023 | 157 | $1.32B |
| Q3 2023 | 144 | $945.9M |
| Q2 2023 | 167 | $1.57B |
| Q1 2023 | 138 | $1.22B |
| Q4 2022 | 137 | $533.3M |
| Q3 2022 | 133 | $398.9M |
| Q2 2022 | 131 | $422.1M |
| Q1 2022 | 140 | $1.19B |
| Q4 2021 | 149 | $1.68B |
| Q3 2021 | 132 | $820.8M |
| Q2 2021 | 139 | $2.16B |
| Q1 2021 | 127 | $1.15B |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Protagonist Therapeutics, Inc; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Magnetar Financial LLC | 0 | $0 | 0.00% | −11,154−100.0% | Sold out |
| Quantessence Capital LLC | 0 | $0 | 0.00% | −8,900−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −8,281−100.0% | Sold out |
| Landscape Capital Management, L.L.C. | 0 | $0 | 0.00% | −7,758−100.0% | Sold out |
| Capula Management Ltd | 0 | $0 | 0.00% | −7,684−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −7,477−100.0% | Sold out |
| SummitTX Capital, L.P. | 0 | $0 | 0.00% | −5,900−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −5,741−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −4,140−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −3,278−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −3,026−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −2,704−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −2,429−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −2,058−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −1,617−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −283−100.0% | Sold out |
| Boston Private Wealth LLC | 0 | $0 | 0.00% | −261−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −99−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −71−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Creative Financial Designs Inc | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Optiver Holding B.V. | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| TFC Financial Management | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Glenmede Trust Co NA | – | – | – | – | Not filed |
| Orion Portfolio Solutions, LLC | – | – | – | – | Not filed |
| CAPROCK Group, Inc. | – | – | – | – | Not filed |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |